{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:02:24Z","timestamp":1791860544597,"version":"4.3.4"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The coronavirus disease 2019 (COVID-19) pandemic prompted policy changes to allow increased telehealth delivery of buprenorphine, a potentially lifesaving medication for opioid use disorder (OUD). It is unclear how characteristics of patients who access different treatment modalities (in-person vs telehealth, video vs telephone) vary, and whether modality is associated with retention\u2014a key indicator of care quality.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To compare patient characteristics across receipt of different treatment modalities and to assess whether modality was associated with retention during the year following COVID-19\u2013related policy changes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study was conducted in the national Veterans Health Administration. Participants included patients who received buprenorphine for OUD during March 23, 2020, to March 22, 2021. Analyses examining retention were stratified by buprenorphine initiation time (year following COVID-19\u2013related changes; prior to COVID-19\u2013related changes).<\/jats:p><\/jats:sec>Exposures<\/jats:title>Patient characteristics; treatment modality (at least 1 video visit, at least 1 telephone visit but no video, only in-person).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Treatment modality; 90-day retention.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 17\u202f182 patients, 7094 (41.3%) were aged 30 to 44 years and 6251 (36.4%) were aged 45 to 64 years; 15\u202f835 (92.2%) were male, 14\u202f085 (82.0%) were White, and 16\u202f292 (94.8%) were non-Hispanic; 6547 (38.1%) had at least 1 video visit, 8524 (49.6%) had at least 1 telephone visit but no video visit, and 2111 (12.3%) had only in-person visits. Patients who were younger, male, Black, unknown race, Hispanic, non\u2013service connected, or had specific mental health\/substance use comorbidities were less likely to receive any telehealth. Among patients who received telehealth, those who were older, male, Black, non\u2013service connected, or experiencing homelessness and\/or housing instability were less likely to have video visits. Retention was significantly higher for patients with telehealth compared with only in-person visits regardless of initiation time (for initiated in year following COVID-19\u2013related changes: adjusted odds ratio [aOR], 1.31; 95% CI, 1.12-1.53; for initiated prior to COVID-19\u2013related changes: aOR, 1.23; 95% CI, 1.08-1.39). Among patients with telehealth, higher retention was observed in those with video visits compared with only telephone for patients who initiated in the year following COVID-19 (aOR, 1.47; 95% CI, 1.26-1.71).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, many patients accessed buprenorphine via telephone and some were less likely to have any video visits. These findings suggest that discontinuing or reducing telephone access may disrupt treatment for many patients, particularly groups with access disparities such as Black patients and those experiencing homelessness. Telehealth was associated with increased retention for both new and continuing patients.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.36298","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T15:11:05Z","timestamp":1665587465000},"page":"e2236298","source":"Crossref","is-referenced-by-count":64,"title":["Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"5","author":[{"given":"Madeline C.","family":"Frost","sequence":"first","affiliation":[{"name":"Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle"},{"name":"Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Myra","family":"Kim","sequence":"additional","affiliation":[{"name":"VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Consulting for Statistics, Computing & Analytics Research (CSCAR), University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewei (Allison)","family":"Lin","sequence":"additional","affiliation":[{"name":"VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"issue":"12","key":"zoi221026r1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamapsychiatry.2020.1698","article-title":"Telehealth for substance-using populations in the age of coronavirus disease 2019: recommendations to enhance adoption.","volume":"77","author":"Lin","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi221026r2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review.","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi221026r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"23","key":"zoi221026r7","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic.","volume":"324","author":"Huskamp","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"zoi221026r8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jamainternmed.2020.7497","article-title":"Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic.","volume":"181","author":"Nguyen","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi221026r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic.","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi221026r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108486","article-title":"Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020.","volume":"219","author":"Jones","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi221026r11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/add.v116.1","article-title":"Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.","volume":"116","author":"Lin","year":"2021","journal-title":"Addiction"},{"issue":"1","key":"zoi221026r12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/08897077.2019.1640831","article-title":"Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what?","volume":"41","author":"Manhapra","year":"2020","journal-title":"Subst Abus"},{"key":"zoi221026r13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi221026r14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/add.v111.2","article-title":"Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.","volume":"111","author":"Pierce","year":"2016","journal-title":"Addiction"},{"issue":"9","key":"zoi221026r15","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/add.v115.9","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction"},{"issue":"1","key":"zoi221026r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42531","article-title":"Use of telemedicine for buprenorphine inductions in patients with commercial insurance or Medicare Advantage.","volume":"5","author":"Barsky","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi221026r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11606-022-07633-y","article-title":"Patient and clinician characteristics associated with use of telemedicine for buprenorphine induction among Medicare beneficiaries.","author":"Patel","year":"2022","journal-title":"J Gen Intern Med"},{"key":"zoi221026r18","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000985","article-title":"Patient characteristics associated with phone versus video telemedicine visits for substance use treatment during COVID-19.","author":"Chang","year":"2022","journal-title":"J Addict Med"},{"key":"zoi221026r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108641","article-title":"A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.","volume":"135","author":"Cunningham","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi221026r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109187","article-title":"Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.","volume":"230","author":"Harris","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi221026r21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12954-021-00578-1","article-title":"Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.","volume":"18","author":"Yeo","year":"2021","journal-title":"Harm Reduct J"},{"issue":"2","key":"zoi221026r22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1037\/rmh0000206","article-title":"Impact of telemedicine on retention in Medications for Opioid Use Disorder (MOUD) treatment with buprenorphine in the times of COVID-19 pandemic: a retrospective chart review.","volume":"46","author":"Kaur","year":"2022","journal-title":"Rural Mental Health"},{"key":"zoi221026r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100055","article-title":"Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.","volume":"3","author":"Ward","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"zoi221026r24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","article-title":"Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps.","volume":"39","author":"Wyse","year":"2018","journal-title":"Subst Abus"},{"issue":"4","key":"zoi221026r25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1089\/tmj.2020.0233","article-title":"Rapid increase in telemental health within the Department of Veterans Affairs during the COVID-19 pandemic.","volume":"27","author":"Connolly","year":"2021","journal-title":"Telemed J E Health"},{"issue":"3","key":"zoi221026r26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/jamiaopen\/ooz024","article-title":"Making connections: nationwide implementation of video telehealth tablets to address access barriers in veterans.","volume":"2","author":"Zulman","year":"2019","journal-title":"JAMIA Open"},{"issue":"3","key":"zoi221026r27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/jamia\/ocaa284","article-title":"Virtual care expansion in the Veterans Health Administration during the COVID-19 pandemic: clinical services and patient characteristics associated with utilization.","volume":"28","author":"Ferguson","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"zoi221026r28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder.","author":"Lin","journal-title":"Am J Psychiatry"},{"key":"zoi221026r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108492","article-title":"Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.","volume":"133","author":"Lin","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi221026r33","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11606-019-05447-z","article-title":"Social determinants and military veterans\u2019 suicide ideation and attempt: a cross-sectional analysis of electronic health record data.","volume":"35","author":"Blosnich","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi221026r34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"issue":"1","key":"zoi221026r35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1044207319875070","article-title":"Compensation for veterans with service connected disabilities: current findings and future implications.","volume":"31","author":"Maynard","year":"2020","journal-title":"J Disabil Policy Stud"},{"issue":"8","key":"zoi221026r36","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.2337\/diacare.26.8.2392","article-title":"Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans.","volume":"26","author":"Young","year":"2003","journal-title":"Diabetes Care"},{"issue":"12","key":"zoi221026r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37238","article-title":"Accessibility to medication for opioid use disorder after interventions to improve prescribing among nonaddiction clinics in the US Veterans Health Care System.","volume":"4","author":"Hawkins","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi221026r38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes.","volume":"42","author":"Zeger","year":"1986","journal-title":"Biometrics"},{"issue":"4","key":"zoi221026r39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation.","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi221026r41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi221026r42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/PHH.0000000000001168","article-title":"Structural racism and the opioid overdose epidemic: the need for antiracist public health practice.","volume":"26","author":"Kunins","year":"2020","journal-title":"J Public Health Manag Pract"},{"key":"zoi221026r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108214","article-title":"Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19.","volume":"122","author":"Nguemeni Tiako","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi221026r44","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/08897077.2022.2095077","article-title":"Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts.","volume":"43","author":"Wakeman","year":"2022","journal-title":"Subst Abus"},{"issue":"6","key":"zoi221026r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic.","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi221026r47","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12699","article-title":"Broadband access and telemedicine adoption for opioid use disorder treatment in the United States.","author":"Ali","year":"2022","journal-title":"J Rural Health"},{"issue":"6","key":"zoi221026r48","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0306-4603(02)00218-6","article-title":"The influence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatment.","volume":"28","author":"Schmitt","year":"2003","journal-title":"Addict Behav"},{"issue":"1","key":"zoi221026r49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12954-021-00572-7","article-title":"Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.","volume":"18","author":"Aronowitz","year":"2021","journal-title":"Harm Reduct J"},{"key":"zoi221026r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms.","volume":"132","author":"Treitler","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi221026r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108999","article-title":"Use of telemedicine for opioid use disorder treatment\u2014perceptions and experiences of opioid use disorder clinicians.","volume":"228","author":"Riedel","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi221026r52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11606-021-07174-w","article-title":"Initiating opioid use disorder medication via telemedicine during COVID-19: implications for proposed reforms to the Ryan Haight Act.","volume":"37","author":"Huskamp","year":"2022","journal-title":"J Gen Intern Med"},{"key":"zoi221026r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108777","article-title":"Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.","volume":"139","author":"Mattocks","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi221026r54","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JAN.0000000000000419","article-title":"Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program.","volume":"32","author":"Moore","year":"2021","journal-title":"J Addict Nurs"},{"issue":"7","key":"zoi221026r55","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10826084.2022.2064509","article-title":"Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities.","volume":"57","author":"Walters","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"1","key":"zoi221026r56","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/08897077.2022.2060447","article-title":"A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.","volume":"43","author":"Lockard","year":"2022","journal-title":"Subst Abus"},{"key":"zoi221026r4","author":"United States Code"},{"key":"zoi221026r30","author":"Department of Veterans Affairs","year":"2020"},{"key":"zoi221026r32","volume-title":"Documentation: 2010 Rural-Urban Commuting Area (RUCA) Codes","author":"Economic Research Service","year":"2016"},{"key":"zoi221026r40","volume-title":"Version 7.1. Copyright","author":"SAS Enterprise Guide Software","year":"2014"},{"key":"zoi221026r5","unstructured":"U.S. Department of Justice Drug Enforcement Administration. DEA qualifying practitioners, DEA qualifying other practitioners. Published 2020. Accessed December 10, 2021. https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf"},{"key":"zoi221026r6","unstructured":"117th Congress. S.987 - CARA 3.0 Act of 2021. Accessed March 17, 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/987\/text"},{"key":"zoi221026r29","unstructured":"Souden? M. Overview of VA data, information systems, national databases and research uses. Published 2017. Accessed July 26, 2019. https:\/\/www.hsrd.research.va.gov\/for_researchers\/cyber_seminars\/archives\/2376-notes.pdf"},{"key":"zoi221026r46","unstructured":"Department of Veterans Affairs. Connecting Veterans to Telehealth Care. Published 2021. Accessed January 31, 2022. https:\/\/connectedcare.va.gov\/sites\/default\/files\/telehealth-digital-divide-fact-sheet.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797201\/frost_2022_oi_221026_1664569325.62174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T15:11:09Z","timestamp":1665587469000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36298","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}